| Date | Title | Description |
| 27.08.2025 | Harbour BioMed Reports 2025 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ... |
| 12.06.2025 | Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases | CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced a license agreement with Visterra, Inc. to advance Vist... |
| 06.10.2017 | Term Sheet — Friday, October 6 | DAYS OF CHANGE
Happy Friday, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
In an effort to woo drivers, Uber launched an initiative called, 180 Days of Change — a campaign that aims to make “meaningful c... |
| 05.10.2017 | Visterra Closes $46.7 Million Series C Financing | Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adeq... |
| 05.10.2017 | Visterra adds $24M to series C to take flu drug to phase 2b | Visterra has extended its series C round to fund the advance of its lead candidate into phase 2b. The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.
Sponsored by Agilent... |
| 05.10.2017 | Visterra Announces $46.7M Series C Funding |
CAMBRIDGE, MA, Visterra, a biotech company, has closed its Series C funding round at $46.7 million.
>> Click here for more funding data on Visterra
>> To export Visterra funding data to PDF and Excel, click here
Visterra,... |
| 05.10.2017 | Visterra adds $24M to series C to take flu drug to phase 2b | Visterra has extended its series C round to fund the advance of its lead candidate into phase 2b. The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.
Cambridge, MA-based ... |
| 05.10.2017 | Visterra Closes $46.7M Series C Financing | Visterra, Inc., a Cambridge, MA – based clinical-stage biotechnology company, completed a Series C financing round raising a total of $46.7m, including a new extension totaling $23.6m.
The Series C financing round included existing investor... |
| 30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. It comes in response to the growing threat of drug-resistant infections — and the concerning lack of late-stage antibacterial dru... |
| 02.10.2014 | Visterra bringing influenza immunotherapy into Phase 2 with $30M cash influx | The financing was led by two new investors: Merck Research Labs Venture Fund and Singapore-based Vertex Venture Holdings. Also participating are existing investors Polaris Partners, Flagship Ventures, Omega Funds and Alexandria Venture Inve... |
| 02.10.2014 | Visterra Completes $30M Series B Financing | Visterra, Inc., a Cambridge, MA-based biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, completed a $30m Series B financing round.
The round was co-led by n... |
| 02.10.2014 | Visterra Closes $30M Series B Financing |
CAMBRIDGE, MA, Biotechnology company has completed a $30 million Series B financing round.
>> Click here for more funding data on Visterra
>> To export Visterra funding data to PDF and Excel, click here
Visterra, Inc., a ... |
| 02.12.2013 | Visterra Closes $8.1M Series A Financing |
CAMBRIDGE, MA, Developer of novel therapeutics to prevent and treat major infectious diseases, today announced that it has received $8.1 million in proceeds.
>> Click here for more funding data on Visterra
>> To export Viste... |
| 02.12.2013 | Flu vaccine developer Visterra gets a Series A boost for clinical trials in 2014 | The Cambridge company has quite a backing — Polaris Venture Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation and Omega Funds participated in this tranche of the Series A. It’s also added two pharma veterans ... |
| 02.12.2013 | Visterra Raises $8.1M in Series A Round | Visterra, Inc., a Cambridge, MA-based developer of novel therapeutics to prevent and treat major infectious diseases, raised $8.1m in funding to close its Series A financing round.
Backers in the financing, which brought total proceeds in S... |
| 16.01.2013 | 5 flu vaccines that could shake up the influenza prevention market | Universal vaccines: Biotechnology startup Visterra is developing a monoclonal antibody for universal flu vaccine VIS410 that could not only cover the three most common seasonal strains the widely available flu vaccines protect against, but ... |
| 09.11.2012 | Visterra completes $26M round to prevent and treat infectious disease | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Of all the noble causes out there, the prevention... |
| 09.11.2012 | Visterra Raises $13M; Completes $26M Series A | Visterra, Inc., a Cambridge, MA-based developer of novel medicines to prevent and treat infectious and other major diseases, has raised an additional $13m to complete a $26M Series A financing.
New backers Bill & Melinda Gates Foundatio... |
| 09.11.2012 | Visterra completes $26M round to prevent and treat infectious disease | Of all the noble causes out there, the prevention of infectious disease is high on the list. This is certainly part of the mission for biotech company Visterra, which has completed a $26 million round of funding to support technology that d... |
| 09.11.2012 | Universal flu vaccine that could improve response to deadlier strains raises $26M | The company’s lead treatment is expected to enter clinical development in the next two years. The investment will be used to develop the company’s technology platform and advance its infectious disease pipeline.
Earlier this fall the Cambri... |
| 09.11.2012 | Visterra Secures $13M Financing |
CAMBRIDGE, MA, Developer of novel medicines to prevent and treat infectious and other major diseases raised an additional $13M to complete a $26M Series A financing.
>> Click here for more funding data on Visterra
>> To expo... |
| - | Flu vaccine developer Visterra gets a Series A boost for clinical trials in 2014 | The annual flu vaccine only prevents against three or four strains of flu-causing viruses that are circulating during any given year. A number of drug companies think more sophisticated vaccines could do better at preventing seasonal and pa... |
| - | 5 flu vaccines that could shake up the influenza prevention market | As people in towns and cities across the U.S. feel the clammy grip of the flu epidemic, several biotechnology startups and Big Pharma companies are using innovative technology to develop different approaches to combating influenza and devel... |
| - | Universal flu vaccine that could improve response to deadlier strains raises $26M | At this time of year, notifications of free flu vaccines are as plentiful as leaves on the ground and pre-Christmas sales. But a biotechnology company is developing a monoclonal antibody for a universal flu vaccine that could not only cover... |
| - | CARB-X dishes out $48M in grants to antimicrobial startups | CARB-X is making it rain.
The international antimicrobial consortium today announced grants totaling $48 million, spread across 11 companies in the U.S. and U.K.
Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteri... |
| - | Visterra bringing influenza immunotherapy into Phase 2 with $30M cash influx | Infectious diseases like dengue fever influenza of the seasonal and pandemic varieties are the top targets for Cambridge biotech Visterra, which has just raised a hefty Series B round – to the tune of $30 million – for its immunotherapies.
... |
